Moderna, Inc. (NASDAQ:MRNA) President Sells $1,694,850.00 in Stock

Moderna, Inc. (NASDAQ:MRNA) President Stephen Hoge sold 15,000 shares of the business’s stock in a transaction that occurred on Friday, September 15th. The stock was sold at an average price of $112.99, for a total value of $1,694,850.00. Following the completion of the sale, the president now owns 1,574,187 shares of the company’s stock, valued at $177,867,389.13. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Stephen Hoge also recently made the following trade(s):

• On Tuesday, August 29th, Stephen Hoge sold 1,135 shares of Moderna stock. The shares were sold at an average price of $115.01, for a total transaction of $130,536.35.
• On Thursday, August 17th, Stephen Hoge sold 15,000 shares of Moderna stock. The stock was sold at an average price of $100.00, for a total transaction of $1,500,000.00.
• On Thursday, August 10th, Stephen Hoge sold 247 shares of Moderna stock. The stock was sold at an average price of $102.53, for a total transaction of $25,324.91.
• On Monday, July 17th, Stephen Hoge sold 15,000 shares of Moderna stock. The shares were sold at an average price of $120.60, for a total value of $1,809,000.00.

Moderna Price Performance

Shares of Moderna stock traded down $10.45 during midday trading on Monday, hitting $104.14. 7,486,037 shares of the company were exchanged, compared to its average volume of 3,628,745. The firm has a 50 day simple moving average of $112.87 and a 200-day simple moving average of $127.93. Moderna, Inc. has a 52 week low of $95.02 and a 52 week high of $217.25. The firm has a market cap of $39.63 billion, a P/E ratio of 39.63 and a beta of 1.63. The company has a debt-to-equity ratio of 0.05, a current ratio of 3.39 and a quick ratio of 3.16.

Moderna (NASDAQ:MRNA) last issued its quarterly earnings data on Thursday, August 3rd. The company reported ($3.62) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($3.84) by $0.22. Moderna had a return on equity of 6.62% and a net margin of 11.33%. The company had revenue of $344.00 million during the quarter, compared to analysts’ expectations of $307.67 million. During the same period last year, the business earned $5.24 earnings per share. The business’s revenue was down 92.8% on a year-over-year basis. Research analysts forecast that Moderna, Inc. will post -4.31 earnings per share for the current year.

Hedge Funds Weigh In On Moderna

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. RB Capital Management LLC increased its holdings in shares of Moderna by 7.5% during the first quarter. RB Capital Management LLC now owns 2,267 shares of the company’s stock worth $391,000 after buying an additional 158 shares in the last quarter. Synovus Financial Corp increased its holdings in Moderna by 8.0% during the 1st quarter. Synovus Financial Corp now owns 4,049 shares of the company’s stock valued at $704,000 after purchasing an additional 300 shares in the last quarter. Dimensional Fund Advisors LP raised its position in Moderna by 5.1% in the 1st quarter. Dimensional Fund Advisors LP now owns 987,478 shares of the company’s stock valued at $170,121,000 after purchasing an additional 47,755 shares during the last quarter. Blair William & Co. IL boosted its stake in Moderna by 12.4% in the first quarter. Blair William & Co. IL now owns 15,611 shares of the company’s stock worth $2,689,000 after purchasing an additional 1,724 shares in the last quarter. Finally, Sei Investments Co. grew its holdings in shares of Moderna by 41.4% during the first quarter. Sei Investments Co. now owns 58,160 shares of the company’s stock worth $10,019,000 after purchasing an additional 17,031 shares during the last quarter. 64.51% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on the company. 51job reissued an “upgrade” rating on shares of Moderna in a research report on Monday, June 26th. Jefferies Financial Group reduced their price objective on Moderna from $275.00 to $175.00 in a research report on Friday, August 4th. UBS Group upgraded shares of Moderna from a “neutral” rating to a “buy” rating and lowered their price objective for the stock from $221.00 to $191.00 in a research note on Monday, June 26th. TD Cowen cut shares of Moderna from an “outperform” rating to a “market perform” rating and cut their target price for the company from $145.00 to $125.00 in a research note on Friday, August 4th. Finally, William Blair began coverage on shares of Moderna in a research report on Monday, July 24th. They issued a “market perform” rating and a $136.28 price target on the stock. Three equities research analysts have rated the stock with a sell rating, nine have assigned a hold rating and six have issued a buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $155.52.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, respiratory syncytial virus, Endemic HCoV, and hMPV+PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella-zoster virus, and human immunodeficiency virus vaccines; and public health vaccines consists of Zika and Nipah vaccines.